Clinical Trial Update: A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing milvexian versus apixaban in patients with atrial fibrillation is ongoing with active/not recruiting status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Apixaban (apixaban)
• Milvexian (milvexian)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Atrial Fibrillation | Phase 3 | Status: ACTIVE_NOT_RECRUITING